Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Experts in Med Tech Regulation and Surgical Technologies join the Medical Sciences Division Industry Experts in Residence Scheme.

Dr Toni Day (left) and Professor Chris Cheng (right)

The Business Development Team for the Medical Sciences Division has announced the appointment of two new  experts to its Industry Experts in Residence Scheme. Dr Toni Day, Director of Quality and Regulatory Affairs at OrganOx, and Professor Chris Cheng, Consulting Professor in Vascular Surgery at Stanford and CEO of medical device company Koli Inc., became part of the scheme in December. 

The Industry Experts in Residence programme is managed by the MSD Business Development Team and Oxford University Innovation. It aims to give Oxford's research community access to world-leading expertise and advice across multiple sectors. Researchers can arrange meetings with industry experts to discuss their ideas and projects, and attend seminars give by these experts on a wide range of topics.

The scheme currently hosts experts in product design in biomedical engineering, drug discovery, and digital health, and the appointment of Dr Day and Professor Cheng has now made their expertise in Med Tech Regulation and Surgical Technologies available to researchers.

Dr Day holds a BSc Honours degree in Biochemistry and a DPhil in Neuropharmacology from the University of Oxford, and has worked for a number of start-up companies in the medical device, in vitro diagnostics and pharmaceutical arenas. She joined OrganOx Ltd in April 2011 to build the Quality Management System and the Regulatory Strategy. Toni commented: 'I am delighted to be part of the Industry Experts in Residence Scheme, and look forward to meeting researchers to discuss medical devices at all levels of the development lifecycle.' She is hosted in Oxford by the Oxford Medical CE Marking Forum (OxMCEF)

Professor Cheng is currently CEO of Koli, Inc., a medical device company developing a catheter-based solution for gallstone disease (spun out of Stanford Biodesign). He is also a Consulting Professor in Vascular Surgery at Stanford. He commented: 'I am thrilled to be at Oxford as part of the Expert in Residence program!  My colleagues in Surgery and Cardiovascular Medicine, as well as the Fellows at Exeter College, have made me feel at home since day one.  While I am here, I look forward to learning about the NHS, and am especially excited about engaging with students and faculty about academic collaborations with the medical device industry.' 

Maxine Allen, Head of Business Development and Partnering for the Medical Sciences Division, commented: 'The Industry Experts in Residence scheme is a fantastic opportunity for our researchers to develop translational strategies for their projects, and an innovative way to foster interaction between industry and academia.'

Find out more about the scheme and book an appointment with an expert 

______________________________________________________________________________________________

Upcoming workshops and talks

Professor Cheng will be running open, small group sessions about biomedical research, the medical device industry, entrepreneurship, choosing between academia and industry, and work-life balance over the coming term. These sessions will be from 2.30-4.30pm on Thurs 25 Jan, Thurs 8 Feb, Thurs 22 Feb, and Thurs 8 March in Exeter College Cohen Quad. Please send Prof. Cheng an email (christopher.cheng@exeter.ox.ac.uk) to confirm a place.  

Further workshops and events: 

Similar stories

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Innovation award for Professor Anindita Roy to develop new treatments for childhood cancer

Awards and Appointments General Innovation Research

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Awards and Appointments Coronavirus COVID-19 General Innovation Research

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

General Innovation

The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

BioEscalator’s Enara Bio partners with Boehringer Ingelheim to develop novel cancer immunotherapies

General Innovation

Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.